Research programme: vaccines - VLP Biotech

Drug Profile

Research programme: vaccines - VLP Biotech

Alternative Names: Allergy vaccine - VLP Biotech; Alzheimer's disease vaccine - VLP Biotech; Atherosclerosis vaccine - VLP Biotech; Cancer vaccine - VLP Biotech; Hepatitis B viral vaccine- VLP Biotech; Hepatitis C virus vaccine - VLP Biotech; Hypersensitivity vaccine - VLP Biotech; Influenza A virus vaccine - VLP Biotech; Lipid disorder vaccine - VLP Biotech; Malaria vaccine - VLP Biotech; Obesity vaccine - VLP Biotech; palivizumab epitope-displaying VLPs; RSV vaccine - VLP Biotech; VLP 206; VLP-162

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChronTech Pharma; Vaccine Research Institute of San Diego
  • Developer MedImmune; VLP Biotech
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Malaria; Respiratory syncytial virus infections

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections
  • No development reported Anthrax; Hepatitis B; Malaria
  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Hepatitis C; Hypersensitivity; Influenza virus infections; Lipid metabolism disorders; Obesity

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for research development in Anthrax in USA
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Hepatitis-B in USA
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Malaria in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top